NASDAQ:BPMC - Blueprint Medicines Stock Price, Forecast & News

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Blueprint Medicines Corp (NASDAQ:BPMC) posted its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($1.93) EPS for the quarter, topping the Zacks' consensus estimate of ($2.19) by $0.26. The biotechnology company had revenue of $9.14 million for the quarter, compared to analyst estimates of $2.85 million. Blueprint Medicines had a negative return on equity of 77.27% and a negative net margin of 2,258.84%. The firm's quarterly revenue was up 734.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.66) earnings per share. View Blueprint Medicines' Earnings History.

Blueprint Medicines is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Blueprint Medicines.

11 brokerages have issued 12 month price targets for Blueprint Medicines' shares. Their forecasts range from $70.00 to $125.00. On average, they expect Blueprint Medicines' stock price to reach $107.36 in the next year. This suggests a possible upside of 34.6% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.

News stories about BPMC stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Blueprint Medicines earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Blueprint Medicines.

Some companies that are related to Blueprint Medicines include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Perrigo (PRGO) and Horizon Therapeutics (HZNP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Nektar Therapeutics (NKTR), Micron Technology (MU), AbbVie (ABBV), STMicroelectronics (STM), Intercept Pharmaceuticals (ICPT), Ionis Pharmaceuticals (IONS), Xilinx (XLNX), Canopy Growth (CGC) and Codexis (CDXS).

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Zeke Capital Advisors LLC (0.02%), Assenagon Asset Management S.A. (0.01%), Steward Partners Investment Advisory LLC (0.00%), Nisa Investment Advisors LLC (0.00%) and Allworth Financial LP (0.00%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.

BPMC stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Zeke Capital Advisors LLC, Steward Partners Investment Advisory LLC, Allworth Financial LP and Nisa Investment Advisors LLC. View Insider Buying and Selling for Blueprint Medicines.

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BPMC stock can currently be purchased for approximately $79.74.

Blueprint Medicines has a market capitalization of $3.92 billion and generates $44.52 million in revenue each year. The biotechnology company earns $-236,640,000.00 in net income (profit) each year or ($5.39) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe.View Additional Information About Blueprint Medicines.

The official website for Blueprint Medicines is http://www.blueprintmedicines.com/.

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]